Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 3.20 is 69% below its 5-year average of 10.29, near the low end of its 5-year range (3.20–21.36).
As of the fiscal period ended Tuesday, June 30, 2026. 21.38% below its 12-month average of 4.07.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.20.
CURRENT RATIO
3.20
CURRENT RATIO AVG TTM
4.07
CURRENT RATIO AVG 3Y
5.25
CURRENT RATIO AVG 5Y
10.29
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-21.38%
CURRENT VS 3Y AVG
-39.07%
CURRENT VS 5Y AVG
-68.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
-14.96%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Current Ratio
3.20
TTM Avg
4.07
3Y Avg
5.25
5Y Avg
10.29
Market Cap
$3.12B
Current Ratio
12.12
TTM Avg
10.47
3Y Avg
8.70
5Y Avg
7.11
Market Cap
$3.31B
Current Ratio
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
Market Cap
$3.03B
Current Ratio
64.07
TTM Avg
24.32
3Y Avg
16.73
5Y Avg
16.77
Market Cap
$3.36B
Current Ratio
17.91
TTM Avg
1.68
3Y Avg
1.68
5Y Avg
1.68
Market Cap
$3.38B
Current Ratio
3.39
TTM Avg
3.10
3Y Avg
3.17
5Y Avg
4.31
Market Cap
$2.99B
Current Ratio
2.92
TTM Avg
3.66
3Y Avg
6.49
5Y Avg
8.50
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | 3.20 | 4.07 | 5.25 | 10.29 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 12.12 | 10.47 | 8.70 | 7.11 |
| CareDx, Inc (CDNA)vs › | $3.30B | 4.58 | 3.40 | 3.98 | 4.25 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 4.72 | 21.21 | 17.30 | 19.05 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 8.37 | 8.81 | 8.76 | 9.71 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 64.07 | 24.32 | 16.73 | 16.77 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 17.91 | 1.68 | 1.68 | 1.68 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.39 | 3.10 | 3.17 | 4.31 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 2.92 | 3.66 | 6.49 | 8.50 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 9.63 | 11.21 | 9.89 | 7.80 |
Current Ratio
3.20
Quick Ratio
3.17
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 3.20 |
| 2026-03-31 | 3.74 |
| 2025-12-31 | 3.85 |
| 2025-09-30 | 4.29 |
| 2025-06-30 | 5.26 |
| 2025-03-31 | 5.57 |
| 2024-12-31 | 4.42 |
| 2024-09-30 | 5.42 |
| 2024-06-30 | 7.03 |
| 2024-03-31 | 8.01 |
| 2023-12-31 | 6.93 |
| 2023-09-30 | 11.15 |
| 2023-06-30 | 12.43 |
| 2023-03-31 | 15.74 |
| 2022-12-31 | 14.61 |
| 2022-09-30 | 16.40 |
| 2022-06-30 | 21.36 |
| 2022-03-31 | 14.18 |
| 2021-12-31 | 15.33 |
| 2021-09-30 | 18.05 |
| 2021-06-30 | 19.22 |
| 2021-03-31 | 18.92 |
| 2020-12-31 | 31.68 |
| 2020-09-30 | 14.50 |
| 2020-06-30 | 17.79 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 70.85 |
| 2019-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
